Novo Nordisk has become a household name thanks to the surge of interest in its products, Ozempic and Wegovy – both considered to be game-changers in the treatment of diabetes and obesity. In this video, Walter Scott Client Investment Manager George Dent and Investment Manager Lindsay Scott discuss their views on the growing obesity and diabetes markets along with their outlook for Novo Nordisk.
Key Takeaways:
- Novo Nordisk’s products are game-changing for the obesity market, with the company likely to surpass its 2025 obesity sales target this year.
- Competition exists but it is not a winner-takes-all market – and we believe that Novo Nordisk alongside Eli Lilly have a significant head start.
- Novo Nordisk’s culture underpins its success, with down-to-earth management that’s not afraid to say when things haven’t gone to plan.
- To meet demand for its obesity drug, the company has increased capacity and diversity of supply via contract manufacturing organizations and investing heavily in internal capacity.
IMPORTANT INFORMATION
All investments involve risk, including the possible loss of principal. Certain investments involve greater or unique risks that should be considered along with the objectives, fees, and expenses before investing. Company information is mentioned only for informational purposes and should not be construed as investment or any other advice. The holdings listed should not be considered recommendations to buy or sell a security.
BNY Mellon Investment Management is one of the world’s leading investment management organizations, encompassing BNY Mellon’s affiliated investment management firms and global distribution companies. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may also be used as a generic term to reference the corporation as a whole or its various subsidiaries generally.
This material has been provided for informational purposes only and should not be construed as investment advice or a recommendation of any particular investment product, strategy, investment manager or account arrangement, and should not serve as a primary basis for investment decisions.
Prospective investors should consult a legal, tax or financial professional in order to determine whether any investment product, strategy or service is appropriate for their particular circumstances. Views expressed are those of the author stated and do not reflect views of other managers or the firm overall. Views are current as of the date of this publication and subject to change.
The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. References to specific securities, asset classes and financial markets are for illustrative purposes only and are not intended to be and should not be interpreted as recommendations. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission.
Walter Scott & Partners Limited (“Walter Scott”) is an investment management firm authorized and regulated in the United Kingdom by the Financial Conduct Authority in the conduct of investment business. Walter Scott is a subsidiary of The Bank of New York Mellon Corporation.
Not FDIC-Insured | No Bank Guarantee | May Lose Value
© 2024 BNY Mellon Securities Corporation, distributor, 240 Greenwich Street, 9th Floor, New York, NY 10286
MARK-457803-2023-11-15
